What is the role of avatrombopag in the treatment of immune thrombocytopenic purpura (ITP)?

Updated: Jun 28, 2019
  • Author: Craig M Kessler, MD, MACP; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print
Answer

Avatrombopag, an oral TPO receptor agonist, was approved by the FDA in June 2019 for adults with chronic ITP who have had an insufficient response to a previous treatment. Results from a phase III randomized trial that supported the approval showed avatrombopag administration resulted in a platelet count of at least 50,000/µL at day eight of therapy in the majority of patients, with efficacy superior to placebo in maintaining platelet counts in the target range during the 6-month treatment period. [65]

Unlike romiplostim, which must be taken on an empty stomach, avatrombopag can be administered with food; unlike eltrombopag, it has not been associated with hepatotoxicity.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!